Beat Q1 but guide maintained—strong ops, macro hedged

Delivered 16.6% YoY; management cited 17% vs stated guidance 14-15%

Q1 delivered 25.2% EBITDA margin vs 100-150 bps expected FY-wide; Q1 beat but FY guidance maintained

Delivered 16.6% YoY, 10% patient volume, 11% test volume since Jan 2025 pricing—math consistent

Delivered 25.7% YoY; slight overstatement but within rounding

Core Diagnostics acquired March 2025 (in base), DAPIC/Agra acquired end-Q1; confirmed organic in numbers

Beat prior guidance midpoint; Tier-2/3 network expansion (300 centers added this quarter) and existing center ramp-up (cycle now 5-6 quarters into payoff) driving volume.

Operating leverage from 17% revenue growth, disciplined cost management, lab automation benefits. Organic business (excl. Core drag) showed healthy expansion even sequentially.

Core Diagnostics integration bearing fruit; now fastest-growing region. Specialty + genomics portfolio expansion via core now live into Metropolis network nationwide.

No raise despite Q1 beat. Indicates management caution on H2 macro (weather, competitive intensity, GLP normalization) or disciplined forecasting. Watch for Q2 guidance shift.

Management passed through GST benefit to consumers. Inflation pass-through deferred; stated willingness to raise 'at appropriate opportunity.' No near-term pricing power.

B2C 13.5%, B2B 6%. Combination of execution (market access in low-diagnosis areas), seasonal momentum, unclear if monsoon delay overflowed Q4 into Q1.

Model exists, running 10+ years. Numbers exact count not available; may acquire or continue arrangement. Further detail promised off-call.

Two-part offering (body/mind screening); X-ray, ECG, sonography included; genomics not yet (waiting for validated predictive science). No individual package targets; overall portfolio expected to grow.

~1% of revenue; minimal bump from price increase (competitors benefited more). Continuing to empanel nationwide; one-time benefit won't recur.

Q1 numbers are organic (Core in base, DAPIC/Agra acquired end-Q1). Maintain 14-15% FY27 guidance; margin expansion 120-150 bps. Volume 9-10% from patient growth, 5-6% from mix.

Rationalization happens once per 18-24 months; low-productivity/quality issues. ~300 closed historically, 500 net adds planned this year. Ratio 1:24 targeting 1:30 by year-end.

Currently Tier-1/early Tier-2 focused. Sequence in new towns: Routine → Specialty → TruHealth. Opportunity to build TruHealth in Tier-1/2 cities still available.

No price increases since Jan 2025. CGHS insignificant. Mix-driven: TruHealth +22%, Specialty +17% within revenue growth. Entirely organic volume & mix.

Not contemplating near-term. Passed GST benefits to consumers this year. Will raise when market 'conducive'; agenda is to pass inflation appropriately.

Not expanding beyond 750 towns currently (deepening only). Lab expansion halted 5 quarters ago. No new cost exposure from new geographies. Productivity from existing & new centers will drive margin to 27-28%.

B2B mostly Specialty (labs, hospitals customers). Competitive intensity normal for 10-15 years; not irrational. Unit economics & quality differentiate. Entrants pursuing volume at low margins stall at ₹50-75 Cr.

Many markets lack strong branded presence. Prefer bolt-ons: strong brand, ethical, positive unit economics, right people, disciplined valuation. Open to larger turnarounds if EPS accretive.

GLP pre-screening tests are common (also for other diseases); doctors write own Rx, not packages. Hard to isolate GLP impact. Early days; trend will play out over time.

No third-party data. Anecdotal from vendors & B2B: smaller/unorganized labs slower growth, smaller ones shutting down. Slow steady pace, no catalyst for rapid shift from 10-15% organized to 30%.

Weather, seasonality unpredictable; difficult to forecast quarter-by-quarter. Sticking to 14-15% annual guidance. Over prior 2 quarters delivered the number; comfortable annually.

Metropolis took price hikes 3 prior years. Skipped this year due to GST pass-through. Will raise when appropriate. CAPEX: ₹65 Cr last year; similar this year for full group.

Once per 18-24 months if unproductive/quality issues. 300 closed end of 2 years; no revenue impact. 500 net adds FY27 will take ratio from 1:24 to ~1:30 target.

Core: high single-digit margin, targeting 25% within 3-4 years from acquisition (~8% end-Q4). TruHealth: already at company level margins. Both accretive to EBITDA growth.

Reaffirmed despite Q1 beat (17% delivered vs 14-15% guide). Management cites weather unpredictability, seasonality. Prior guidance maintained suggests caution on H2.

Q1 delivered 210 bps, exceeding expectation. Lab automation, productivity initiatives rolling out; Core integration headwind diminishing. Tier-2/3 expansion stabilizing at current depth (750 towns, no new geographies).

Lab expansion halted; focus on deepening within 750 towns, center expansion, network optimization. Capex discipline suggests margin target achievable without major new infra.

Q1 normally weak; beat this year due to 'seasonal momentum' & delayed monsoon. Weather unpredictable, impacts disease incidence & testing volumes. Management cautious on forecasting.

No price increases since January 2025 (GST pass-through). Inflation ongoing; only ~1% of revenue from CGHS (price increase benefit minimal vs competitors). Consumer resistance, competitive pressure limit near-term pricing.

Industry sees entrants pursuing volume at high servicing costs; most plateau at ₹50-75 Cr revenue and exit/stagnate. Metropolis positioned on quality/Specialty, but B2B customers (smaller labs) price-constrained.

Core acquisition (March 2025) still ~8-9% EBITDA margin, dragging consolidated margin profile. Three-to-four-year journey to 25% target. Genomics upside dependent on successful cross-selling via Metropolis network.

Anecdotal evidence of unorganized labs losing volume; small independents shutting down. But shift from 10-15% to 30% organized market is multi-year, no near-term catalyst. Macro shift could accelerate if regulation tightens (e.g., quality mandates).